Patents Assigned to Signal Pharmaceuticals
  • Treatment of cancer with TOR kinase inhibitors
    Patent number: 9493466
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: November 15, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Antonia Lopez-Girona, Heather Raymon, Rama K. Narla, Rajesh Chopra
  • Methods for treating cancer using TOR kinase inhibitor combination therapy
    Patent number: 9474757
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of a 5-Substituted Quinazolinone Compound to a patient having a cancer.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: October 25, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Kristen Mae Hege, Rajesh Chopra
  • Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
    Patent number: 9434735
    Abstract: Provided herein is an amorphous form of 4-((4-(Cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-N-methylbenzamide, compositions thereof, and methods of their use for treating or preventing a cancer, in particular solid tumors and hematological cancers as described herein.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: September 6, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Ming J. Chen, Jale Muslehiddinoglu, Alexander Ruchelman, Terrence Joseph Connolly
  • Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 9428509
    Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: August 30, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Andrew Antony Calabrese, Brandon Jeffy, Dale Robinson, Dan Zhu, Dehua Huang, Jan Elsner, John Boylan, Lida Tehrani, Mark A. Nagy, Raj Kumar Raheja, Paul Erdman, Rama K. Narla, Roy L. Harris, Tam Minh Tran, Jennifer Riggs, Yuhong Ning, Shuichan Xu
  • Solid forms of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, as TOR kinase inhibitors
    Patent number: 9416134
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to the Compound for formula 1: having the name 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4 -dihydropyrazino[2,3-b]pyrazin-2(1H)-one and tautomers thereof.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: August 16, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventor: Jeffrey Eckert
  • Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-]pyrazin-2(1)-one, a solid form thereof and methods of their use
    Patent number: 9403829
    Abstract: Provided herein are compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, solid forms, isotopologues and metabolites thereof, and methods of their use for the treatment of a disease, disorder, or condition.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: August 2, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Terrence Joseph Connolly, Kevin Joseph Klopfer, William Wei-Hwa Leong, Anil Menon, Amanda Nicole Miklos, Nathan Boersen, Benjamin Cohen, Juan Antonio Gamboa, Ho-Wah Hui, Matthew Michael Kreilein, Thomas Lee, Ying Li, Jean Xu
  • Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib
    Patent number: 9375443
    Abstract: Provided herein are methods for treating or preventing advanced non-small cell lung cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of erlotinib or a cytidine analog to a patient having advanced non-small cell lung cancer.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: June 28, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Tam Minh Tran
  • Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
    Patent number: 9365524
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: June 14, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Hon-Wah Man, Jean Xu, Marie Georges Beauchamps, Mohit Atul Kothare, Nanfei Zou, Ying Li, Lianfeng Huang, Daozhong Zou
  • Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one
    Patent number: 9359364
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: June 7, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Anil Menon, Darshan K. Parikh, Dora Visky, Matthew Michael Kreilein, Nathan Boersen, Thomas Lee, Ying Li, Jean Xu, Xiaozhang Liang, William Wei-Hwa Leong, Benjamin Cohen
  • Methods for treating cancer using TOR kinase inhibitor combination therapy
    Patent number: 9358232
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide to a patient having a cancer.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: June 7, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Kristen Mae Hege, Rajesh Chopra
  • Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 9346812
    Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: May 24, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Andrew Antony Calabrese, Brandon Jeffy, Dale Robinson, Dan Zhu, Dehua Huang, Jan Elsner, John Boylan, Lida Tehrani, Mark A. Nagy, Raj Kumar Raheja, Paul Erdman, Rama K. Narla, Roy L. Harris, Tam Minh Tran, Jennifer Riggs, Yuhong Ning, Shuichan Xu
  • Pharmaceutical formulations of a substituted diaminopurine
    Patent number: 9198866
    Abstract: Provided herein are pharmaceutical formulations, comprising 4-((9-((3S)-tetrahydro-3-furanyl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)-trans-cyclohexanol, including pharmaceutically acceptable salts, solvates, isomers, isotopologues, tautomers and racemic mixtures thereof, and a pharmaceutically acceptable excipient; and their use for treating or preventing disease.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: December 1, 2015
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sreenivas S. Bhat, Xiaozhong Liang, Anthony Tutino, Anthony Joseph Frank
  • SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20150336901
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Application
    Filed: July 31, 2015
    Publication date: November 26, 2015
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Brydon L. Bennett, Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Laurie Ann LeBrun, Meg McCarrick, Mehran F. Moghaddam, Mark A. Nagy, Stephen Norris, David A. Paisner, William J. Romanow, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors
    Patent number: 9193692
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof. Furthermore, provided herein are compounds having the following formulas (IV), (V), (VII) and (VIII): wherein R, R2, R3, R4, Hal and Hal2 are as defined herein, for preparation of the Heteroaryl Compounds.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: November 24, 2015
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella I. Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Jan Elsner
  • Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
    Patent number: 9187479
    Abstract: Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: November 17, 2015
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Steven Clareen, Veronique Plantevin-Krenitsky, Moorthy Palanki, Yoshitaka Satoh
  • Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
    Patent number: 9156798
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: October 13, 2015
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sogole Bahmanyar, Andrew Antony Calabrese, Daniel Cashion, Brian Edwin Cathers, Matthew Correa, Maria Mercedes Delgado, Joshua Hansen, Sayee Hegde, Dehua Huang, Katerina Leftheris, Deborah Mortensen, Stephen Norris, Patrick Papa, Jason Parnes, Veronique Plantevin-Krenitsky, Raj Kumar Raheja, John Sapienza, Eduardo Torres, Brandon Wade Whitefield
  • Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
    Patent number: 9155736
    Abstract: Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: October 13, 2015
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Weiming Xu, Deborah Mortensen, Shuichan Xu, Kimberly Elizabeth Fultz
  • Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
    Patent number: 9139534
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: September 22, 2015
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Brydon L. Bennett, Jan Elsner, Paul Erdman, Robert Hilgraf, Laurie Ann LeBrun, Meg McCarrick, Mehran F. Moghaddam, Mark A. Nagy, Stephen Norris, David A. Paisner, Marianne Sloss, William J. Romanow, Yoshitaka Satoh, Jayashree Tikhe, Won Hyung Yoon, Mercedes Delgado
  • Methods of synthesis and purification of heteroaryl compounds
    Patent number: 9079900
    Abstract: Provided herein are methods to prepare Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein. The Heteroaryl compounds are useful for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: July 14, 2015
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Gingsee Lee, Garrick Packard, Jingjing Zhao, Patrick Anthony Jokiel, Deborah Mortensen, Jennifer Riggs, Juan Antonio Gamboa, Marie Georges Beauchamps, Matthew Michael Kreilein, Mohit Atul Kothare, Sophie Perrin-Ninkovic, Philip Pye, William Wei-Hwa Leong, Jan Elsner, Anusuya Choudhury
  • Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
    Patent number: 8907087
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: December 9, 2014
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella I. Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Jan Elsner